SLDB

Solid Biosciences LLC

SLDB, USA

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

https://www.solidbio.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SLDB
stock
SLDB

Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of “Moderate Buy” by Brokerages Defense World

Read more →
SLDB
stock
SLDB

Solid Biosciences (NASDAQ:SLDB) Research Coverage Started at Needham & Company LLC Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$15.1667

Analyst Picks

Strong Buy

7

Buy

5

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

High

2.54

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-21.00 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-16.71 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.26

Low 1

High 0.3

Investors

* Institutions hold a combined 107.23% of the total shares of Solid Biosciences LLC

1.

Perceptive Advisors LLC

(15.2906%)

since

2025/06/30

2.

Bain Capital Life Sciences Investors, LLC

(10.1602%)

since

2025/06/30

3.

Siren, L.L.C.

(9.5236%)

since

2025/06/30

4.

Adage Capital Partners Gp LLC

(8.642%)

since

2025/06/30

5.

RA Capital Management, LLC

(7.4629%)

since

2025/06/30

6.

BlackRock Inc

(6.3184%)

since

2025/06/30

7.

Vanguard Group Inc

(4.3221%)

since

2025/06/30

8.

FMR Inc

(4.0817%)

since

2025/06/30

9.

Fidelity Select Biotechnology

(3.6828%)

since

2025/07/31

10.

Citadel Advisors Llc

(3.2404%)

since

2025/06/30

11.

Monashee Investment Management LLC

(2.7803%)

since

2025/06/30

12.

Redmile Group, LLC

(2.4604%)

since

2025/06/30

13.

Vanguard Total Stock Mkt Idx Inv

(2.3992%)

since

2025/07/31

14.

Nantahala Capital Management, LLC

(2.1874%)

since

2025/06/30

15.

Alyeska Investment Group, L.P.

(2.1072%)

since

2025/06/30

16.

MPM Oncology Impact Management LP

(2.0991%)

since

2025/06/30

17.

Franklin Resources Inc

(2.0537%)

since

2025/06/30

18.

iShares Russell 2000 ETF

(2.0339%)

since

2025/08/31

19.

Geode Capital Management, LLC

(1.9393%)

since

2025/06/30

20.

Vestal Point Capital LP

(1.9327%)

since

2025/06/30

21.

Point72 Asset Management, L.P.

(1.6259%)

since

2025/06/30

22.

Millennium Management LLC

(1.4118%)

since

2025/06/30

23.

Franklin Biotechnology Discv A(acc)USD

(1.3256%)

since

2025/08/31

24.

Finepoint Capital LP

(1.2344%)

since

2025/06/30

25.

Fidelity Small Cap Index

(0.8518%)

since

2025/06/30

26.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8253%)

since

2025/07/31

27.

International Biotechnology Ord

(0.7474%)

since

2025/07/31

28.

iShares Russell 2000 Value ETF

(0.7353%)

since

2025/08/31

29.

Franklin Biotechnology Discovery A

(0.7278%)

since

2025/07/31

30.

iShares Biotechnology ETF

(0.4293%)

since

2025/08/31

31.

Fidelity Extended Market Index

(0.4115%)

since

2025/07/31

32.

Vanguard Russell 2000 ETF

(0.4042%)

since

2025/07/31

33.

Nuveen Equity Index R6

(0.3968%)

since

2025/07/31

34.

State St Russell Sm Cap® Indx SL Cl I

(0.2991%)

since

2025/08/31

35.

Schwab Small Cap Index

(0.213%)

since

2025/07/31

36.

NT R2000 Index Fund - NL

(0.2051%)

since

2025/06/30

37.

iShares Micro-Cap ETF

(0.1929%)

since

2025/08/31

38.

NT R2000 Index Fund - DC - NL - 3

(0.1636%)

since

2025/06/30

39.

Extended Equity Market Fund K

(0.1611%)

since

2025/06/30

40.

Fidelity Total Market Index

(0.1547%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-0.48

EPS Estimate

-0.4407

EPS Difference

-0.0393

Surprise Percent

-8.9176%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.